Log in

Relevant bibliographies by topics / Fu ci / Journal articles

To see the other types of publications on this topic, follow the link: Fu ci.

Journal articles on the topic 'Fu ci'

Author: Grafiati

Published: 25 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fu ci.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kim, Hoyon, Jamie C. Little, Jiashen Li, Bryna Patel, and Daniel Kalderon. "Hedgehog-stimulated phosphorylation at multiple sites activates Ci by altering Ci–Ci interfaces without full Suppressor of Fused dissociation." PLOS Biology 23, no. 4 (2025): e3003105. https://doi.org/10.1371/journal.pbio.3003105.

Full text

Abstract:

Hedgehog (Hh) proteins elicit dose-dependent transcriptional responses by binding Patched receptors to activate transmembrane Smoothened (Smo) proteins. Activated Smo inhibits Ci/Gli transcription factor phosphorylation by Protein Kinase A and consequent proteolytic processing to repressor forms; it also promotes nuclear transport and activity of full-length Ci/Gli proteins to induce Hh target genes. Smo-activated Fused (Fu) kinase drives Ci activation in Drosophila, while Suppressor of Fused (Su(fu)) counters full-length Ci/Gli activity and stabilizes full-length Ci/Gli by direct binding to a

APA, Harvard, Vancouver, ISO, and other styles

2

Methot, N., and K. Basler. "Suppressor of fused opposes hedgehog signal transduction by impeding nuclear accumulation of the activator form of Cubitus interruptus." Development 127, no. 18 (2000): 4001–10. http://dx.doi.org/10.1242/dev.127.18.4001.

Full text

Abstract:

Hedgehog controls the expression of key developmental genes through the conversion of the transcription factor Cubitus interruptus (Ci) into either an activator (Ci[act]) or a repressor (Ci[rep]) form. Proteolytic cleavage of full-length Ci is important for the generation of Ci[rep], but little is known about how Ci[act] arises in response to Hh. Here we examine Hh signal transduction components for their role in the conversion of full-length Ci into either Ci[act] or Ci[rep]. We report that Cos2, PKA and Fused are necessary for the generation of Ci[rep], whereas the inhibition of either Cos2

APA, Harvard, Vancouver, ISO, and other styles

3

Zhou, Mengmeng, Yuhong Han, Bing Wang, Yong Suk Cho, and Jin Jiang. "Dose-dependent phosphorylation and activation of Hh pathway transcription factors." Life Science Alliance 5, no. 11 (2022): e202201570. http://dx.doi.org/10.26508/lsa.202201570.

Full text

Abstract:

Graded Hedgehog (Hh) signaling is mediated by graded Cubitus interruptus (Ci)/Gli transcriptional activity, but how the Hh gradient is converted into the Ci/Gli activity gradient remains poorly understood. Here, we show that graded Hh induces a progressive increase in Ci phosphorylation at multiple Fused (Fu)/CK1 sites including a cluster located in the C-terminal Sufu-binding domain. We demonstrated that Fu directly phosphorylated Ci on S1382, priming CK1 phosphorylation on adjacent sites, and that Fu/CK1-mediated phosphorylation of the C-terminal sites interfered with Sufu binding and facili

APA, Harvard, Vancouver, ISO, and other styles

4

Köhne, C.-H., J. Wils, M. Lorenz, et al. "Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952." Journal of Clinical Oncology 21, no. 20 (2003): 3721–28. http://dx.doi.org/10.1200/jco.2003.11.122.

Full text

Abstract:

Purpose: This trial was conducted to determine whether high-dose fluorouracil (FU) given as a weekly 24-hour infusion is more active than bolus FU + leucovorin (LV), and whether high-dose infusional FU can be modulated by LV. Patients and Methods: A total of 497 patients with previously untreated metastatic colorectal cancer were randomly assigned to receive bolus FU 425 mg/m2 intravenously + LV 20 mg/m2 on days 1 to 5 and repeated on day 28 (FU + LV), or FU 2,600 mg/m2 as a 24-hour infusion alone (FU24h) or in combination with 500 mg/m2 LV (FU24h + LV)—all given weekly ×6 followed by a 2-week

APA, Harvard, Vancouver, ISO, and other styles

5

Kabbinavar, Fairooz, Herbert I. Hurwitz, Louis Fehrenbacher, et al. "Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer." Journal of Clinical Oncology 21, no. 1 (2003): 60–65. http://dx.doi.org/10.1200/jco.2003.10.066.

Full text

Abstract:

Purpose: This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer. Patients and Methods: One hundred four previously untreated patients with measurable metastatic colorectal cancer were randomly assigned to one of the following three treatment groups: 36 to FU (500 mg/m2)/LV (500 mg/m2) alone, 35 to FU/LV + low-dose bevacizumab (5 mg/kg every 2 weeks), and 33 to FU/LV + high-dose bevacizumab (10 mg/kg e

APA, Harvard, Vancouver, ISO, and other styles

6

Ku, Geoffrey Yuyat, Benjamin Haaland, and Gilberto de Lima Lopes. "Cetuximab (C225) in the first-line treatment of advanced colorectal cancer (CRC) patients (Pts) with K-ras wild-type (WT) tumors: Does the choice and schedule of fluoropyrimidine (Fp) matter?" Journal of Clinical Oncology 30, no. 4_suppl (2012): 576. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.576.

Full text

Abstract:

576 Background: C225, a monoclonal antibody against the epidermal growth factor receptor, has been shown to inconsistently improve response rates (RR), progression-free survival (PFS) and overall survival (OS) in the first-line treatment of advanced CRC Pts with K-ras WT tumors. Methods: We performed a meta-analysis of four trials where K-ras WT Pts received a Fp (capecitabine (C) or bolus (b) or infusional (CI) 5-fluorouracil (5-FU)) and oxaliplatin (oxali) or irinotecan (CPT) ± C225 (CRYSTAL, OPUS, COIN and NORDIC VII trials) and one trial, where K-ras WT and mutant Pts received C225 with ca

APA, Harvard, Vancouver, ISO, and other styles

7

Wang-Gillam, Andrea, Chung-Pin Li, Gyorgy Bodoky, et al. "Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy." Journal of Clinical Oncology 34, no. 4_suppl (2016): 417. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.417.

Full text

Abstract:

417 Background: NAPOLI-1 is a global, randomized Phase 3 study evaluating nal-IRI—a nanoliposomal irinotecan—with or without 5-FU/LV in 417 patients with mPAC previously treated with gemcitabine-based therapy. Primary survival analysis was based on 313 events. Nal-IRI+5FU/LV significantly improved overall survival (OS, primary endpoint), 6.1 months (mo) vs 4.2 mo; with 5-FU/LV (unstratified hazard ratio [HR] = 0.67; P = 0.012). Primary endpoint was supported by improved progression-free survival, time to treatment failure, objective response and CA19-9 tumor marker response rates, and manageab

APA, Harvard, Vancouver, ISO, and other styles

8

Wagner, Anna D., Wilfried Grothe, Johannes Haerting, Gerhard Kleber, Axel Grothey, and Wolfgang E. Fleig. "Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data." Journal of Clinical Oncology 24, no. 18 (2006): 2903–9. http://dx.doi.org/10.1200/jco.2005.05.0245.

Full text

Abstract:

Purpose This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods Randomized phase II and III clinical trials on first-line chemotherapy in advanced gastric cancer were identified by electronic searches of Medline, Embase, the Cochrane Controlled Trials Register, and Cancerlit; hand searches of relevant abstract books and reference lists; and contact to experts. Meta-analysis was performed using the fixed-effect model. Overall survival, reported as hazard ratio (HR) with 95% CI, was the prim

APA, Harvard, Vancouver, ISO, and other styles

9

Arkenau, Hendrik-Tobias, Dirk Arnold, Jim Cassidy, et al. "Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials." Journal of Clinical Oncology 26, no. 36 (2008): 5910–17. http://dx.doi.org/10.1200/jco.2008.16.7759.

Full text

Abstract:

PurposeSix randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer. This meta-analysis compared the efficacy of CAP/OX compared with infusional FU/OX.Patients and MethodsThis analysis compared all published CAP/OX versus infusional FU/OX regimens. A total of 3,494 patients (FU, n = 1,737; CAP, n = 1,757) were analyzed for response rate (RR), progression-free (PFS), overall survival (OS), and toxicity.ResultsThe fixed-effect pooled estimate for RR showed higher RR for

APA, Harvard, Vancouver, ISO, and other styles

10

Nam, Ki-Woong, Chi Kyung Kim, Tae Jung Kim, et al. "FLAIR vascular hyperintensities predict early ischemic recurrence in TIA." Neurology 90, no. 9 (2018): e738-e744. http://dx.doi.org/10.1212/wnl.0000000000005034.

Full text

Abstract:

ObjectiveTo evaluate the relationship between fluid-attenuated inversion recovery (FLAIR) vascular hyperintensity (FVH) and early ischemic lesion recurrence (follow-up diffusion-weighted imaging [FU-DWI] [+]) in patients with lesion-negative TIA.MethodsWe recruited consecutive patients with lesion-negative TIA within 24 hours of symptom onset, who underwent follow-up MRI during the acute period. FVH was defined as a focal or serpentine high signal intensity on FLAIR images. Other potential confounders were adjusted to evaluate the relationship between FVH and FU-DWI (+). Furthermore, to compar

APA, Harvard, Vancouver, ISO, and other styles

11

Poplin, Elizabeth A., Jacqueline K. Benedetti, Norman C. Estes, et al. "Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer." Journal of Clinical Oncology 23, no. 9 (2005): 1819–25. http://dx.doi.org/10.1200/jco.2005.04.169.

Full text

Abstract:

Purpose Modest toxicity and possibly enhanced activity makes continuous-infusion fluorouracil (FU) an attractive alternative to FU plus leucovorin (FU/LV) for the adjuvant treatment of colorectal cancer. Intergroup trial 0153 (Southwest Oncology Group trial 9415) was developed to compare the efficacy of continuous-infusion FU (CIFU) plus levamisole to FU/LV plus levamisole in the adjuvant treatment of high-risk Dukes' B2 and C1 or C2 colon cancer. Patients and Methods After surgery, patients were randomly assigned to CIFU 250 mg/m2/d for 56 days every 9 weeks for three cycles or FU 425 mg/m2 a

APA, Harvard, Vancouver, ISO, and other styles

12

Sisson, Barbara E., Suzanne L. Ziegenhorn, and Robert A. Holmgren. "Regulation of Ci and Su(fu) nuclear import in Drosophila." Developmental Biology 294, no. 1 (2006): 258–70. http://dx.doi.org/10.1016/j.ydbio.2006.02.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Honing, Judith, Justin Smit, Christina Muijs, et al. "A comparison of carboplatin with paclitaxel and cisplatinum with 5-fluorouracil in definitive chemoradiotherapy in esophageal cancer patients." Journal of Clinical Oncology 32, no. 3_suppl (2014): 104. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.104.

Full text

Abstract:

104 Background: In esophageal cancer (EC) patients not eligible for surgery definitive chemoradiation (dCRT) with curative intent using cisplatinum with 5-fluorouracil (5-FU) is the standard regime. Nowadays carboplatin and paclitaxel are also often used. In this study we compared survival and toxicity rates between both regimens. Methods: This multicentre study included 102 patients treated in five centres in the North Netherlands from 1996 till 2008. Forty-seven patients received cisplatinum/5-FU and 55 patients carboplatin/paclitaxel. Results: Overall survival (OS) was not different between

APA, Harvard, Vancouver, ISO, and other styles

14

Schilsky, Richard L., Jeremey Levin, William H. West, et al. "Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer." Journal of Clinical Oncology 20, no. 6 (2002): 1519–26. http://dx.doi.org/10.1200/jco.2002.20.6.1519.

Full text

Abstract:

PURPOSE: To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer. PATIENTS AND METHODS: This multicenter, randomized, open-label, phase III study (FUMA3008) conducted in the United States and Canada compared the safety and efficacy of EU/5-FU (11.5 mg/m2/1.15 mg/m2 twice daily for 28 days every 35 days) with that of intravenous 5-FU/LV (425 mg/m2/20 mg/m2 once daily for 5 days every 28 days) in patients with previously untreated metastatic colorectal cancer. O

APA, Harvard, Vancouver, ISO, and other styles

15

Sultana, Asma, Catrin Tudur Smith, David Cunningham, Naureen Starling, John P. Neoptolemos, and Paula Ghaneh. "Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer." Journal of Clinical Oncology 25, no. 18 (2007): 2607–15. http://dx.doi.org/10.1200/jco.2006.09.2551.

Full text

Abstract:

PurposeThere are a large number of randomized controlled trials involving chemotherapy in the management of advanced pancreatic cancer. Several chemotherapeutic agents, either alone or in combination with other chemotherapy or novel agents, have been used. The aim of these meta-analyses was to examine the different therapeutic approaches, and the comparisons examined were as follows: chemotherapy versus best supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gemcitabine versus gemcitabine combination chemotherapy.MethodsRelevant trials were identi

APA, Harvard, Vancouver, ISO, and other styles

16

Rao, Sheela, Francesco Sclafani, Cathy Eng, et al. "International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct." Journal of Clinical Oncology 38, no. 22 (2020): 2510–18. http://dx.doi.org/10.1200/jco.19.03266.

Full text

Abstract:

PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective r

APA, Harvard, Vancouver, ISO, and other styles

17

Schmoll, Hans-Joachim, Josep Tabernero, Jean Alfred Maroun, et al. "Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA)." Journal of Clinical Oncology 30, no. 4_suppl (2012): 388. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.388.

Full text

Abstract:

388 Background: The MOSAIC trial demonstrated that adding oxaliplatin to 5-FU/LV (FOLFOX4) improved 3-year disease-free survival (DFS) compared to infusional and bolus 5-FU/LV as adjuvant therapy in patients (pts) with stage II/III colon cancer [André et al. NEJM 2004]. A significant survival advantage for FOLFOX4 versus 5-FU/LV was not evident until after median duration of follow-up had exceeded 6 years [André et al. JCO 2009]. Study NO16968 demonstrated that XELOX was superior to bolus 5-FU/LV as adjuvant therapy in pts with stage III colon cancer in terms of DFS at 57 months median follow-

APA, Harvard, Vancouver, ISO, and other styles

18

Douillard, Jean-Yves, Paulo M. Hoff, Jamey R. Skillings, et al. "Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer." Journal of Clinical Oncology 20, no. 17 (2002): 3605–16. http://dx.doi.org/10.1200/jco.2002.04.123.

Full text

Abstract:

PURPOSE: This phase III study was designed to demonstrate equivalence in survival of oral uracil/tegafur (UFT) and oral leucovorin (LV) to conventional intravenous (IV) fluorouracil (5-FU) and LV in previously untreated metastatic colorectal carcinoma. Safety was also compared. PATIENTS AND METHODS: Eight hundred sixteen patients were randomized to receive either UFT (300 mg/m2/d) and LV (75 or 90 mg/d) for 28 days every 35 days or IV bolus 5-FU (425 mg/m2/d) and LV (20 mg/m2/d) for 5 days every 28 days. RESULTS: UFT/LV produced survival comparable to the IV 5-FU/LV regimen. Median survival wa

APA, Harvard, Vancouver, ISO, and other styles

19

Cassidy, J., N. Scotto, and E. Diaz-Rubio. "Review of completed and ongoing trials of capecitabine-based adjuvant therapy in patients with early-stage colon cancer." Journal of Clinical Oncology 29, no. 4_suppl (2011): 495. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.495.

Full text

Abstract:

495 Background: Capecitabine is an established alternative to 5-FU in gastrointestinal cancers. In metastatic colorectal cancer, capecitabine is non-inferior to 5-FU and capecitabine + oxaliplatin (XELOX) is non-inferior to FOLFOX4. Capecitabine is also an effective adjuvant treatment for early-stage colon cancer. Here we review the evidence available from completed studies of adjuvant capecitabine and describe ongoing trials in this setting. Methods: The X-ACT trial included 1,987 patients (pts) with resected stage III disease receiving either capecitabine (n=1,004) or bolus 5-FU/LV (n=983).

APA, Harvard, Vancouver, ISO, and other styles

20

Jeeunngoi, Jarckrit, Gulsiri Senawong, Sanun Jogloy, et al. "Anticancer Potential of Valencia Peanut (Arachis hypogaea L.) Skin Extract against Cervical Cancer Cells In Vitro and in Nude Mouse Xenograft Models." Foods 13, no. 15 (2024): 2354. http://dx.doi.org/10.3390/foods13152354.

Full text

Abstract:

This study investigated the impact of Valencia KK4-type peanut skin ethanolic extract (KK4-PSE) combined with cisplatin or 5-fluorouracil (5-FU) on HeLa cells in vitro and in xenograft models. At exposure times of 24, 48 and 72 h, KK4-PSE inhibited the growth of HeLa cells with a half maximal inhibitory concentration (IC50) of 79.43 ± 0.54, 55.55 ± 1.57 and 41.32 ± 0.74 µg/mL, respectively. Drug interactions evaluated by the Chou–Talalay method demonstrated that KK4-PSE enhanced antiproliferative activity of 5-FU against HeLa cells with combination index (CI) values of 0.49 (48 h) and 0.60 (72

APA, Harvard, Vancouver, ISO, and other styles

21

Merchant, Mark, Felix F. Vajdos, Mark Ultsch, et al. "Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism." Molecular and Cellular Biology 24, no. 19 (2004): 8627–41. http://dx.doi.org/10.1128/mcb.24.19.8627-8641.2004.

Full text

Abstract:

ABSTRACT The Hedgehog pathway drives proliferation and differentiation by activating the Gli/Ci family of zinc finger transcription factors. Gli/Ci proteins form Hedgehog signaling complexes with other signaling components, including the kinesin-like protein Costal-2, the serine-threonine kinase Fused, and Suppressor of Fused [Su(fu)]. In these complexes Gli/Ci proteins are regulated by cytoplasmic sequestration, phosphorylation, and proteolysis. Here we characterize structural and functional determinants of Su(fu) required for Gli regulation and show that Su(fu) contains at least two distinct

APA, Harvard, Vancouver, ISO, and other styles

22

Maisey, Nick, Ian Chau, David Cunningham, et al. "Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer." Journal of Clinical Oncology 20, no. 14 (2002): 3130–36. http://dx.doi.org/10.1200/jco.2002.09.029.

Full text

Abstract:

PURPOSE: To compare protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin (MMC) in patients with advanced pancreatic cancer in a multicenter, prospectively randomized study. PATIENTS AND METHODS: Two hundred eight patients were randomized to PVI 5-FU (300 mg/m2/d for a maximum of 24 weeks) or PVI 5-FU plus MMC (7 mg/m2 every 6 weeks for four courses). The major end points were tumor response, survival, toxicity, and quality of life (QOL). RESULTS: The two treatment groups were balanced for baseline demographic factors, and 62% had metastatic disease. The overall res

APA, Harvard, Vancouver, ISO, and other styles

23

Yang Seoung Duk. "A Study on the Ci-Fu Thoughts of Xie-Ling-Yun." Journal of Chinese Language and Literature ll, no. 54 (2009): 83–104. http://dx.doi.org/10.15792/clsyn..54.200912.83.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Yang, Seoung Duk. "A Study on The theory of Dong-Jin,s Ci-Fu." JOURNAL OF CHINESE HUMANITIES 76 (December 31, 2020): 223–43. http://dx.doi.org/10.35955/jch.2020.12.76.223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bertagnolli, Monica M., Donna Niedzwiecki, Carolyn C. Compton, et al. "Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803." Journal of Clinical Oncology 27, no. 11 (2009): 1814–21. http://dx.doi.org/10.1200/jco.2008.18.2071.

Full text

Abstract:

Purpose Colon cancers exhibiting DNA mismatch repair (MMR) defects demonstrate distinct clinical and pathologic features, including better prognosis and reduced response to fluorouracil (FU) –based chemotherapy. This prospective study investigated adjuvant chemotherapy containing FU and irinotecan in patients with MMR deficient (MMR-D) colon cancers. Patients and Methods Cancer and Leukemia Group B 89803 randomly assigned 1,264 patients with stage III colon cancer to postoperative weekly bolus FU/leucovorin (LV) or weekly bolus irinotecan, FU, and LV (IFL). The primary end point was overall su

APA, Harvard, Vancouver, ISO, and other styles

26

Wang-Gillam, Andrea, Richard Hubner, Beloo Mirakhur, Floris A. de Jong, Bruce Belanger, and Li-Tzong Chen. "Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy." Journal of Clinical Oncology 36, no. 4_suppl (2018): 388. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.388.

Full text

Abstract:

388 Background: In NAPOLI-1 (NCT01494506), a randomized phase 3 study in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy, nal-IRI+5-FU/LV improved overall survival (OS; primary endpoint) vs 5-FU/LV (6.1 mos vs 4.2 mos; HR = 0·67, 95% CI 0.490.92; P = 0.012). This exploratory analysis examined the impact of dose modifications or delays used to manage adverse events (AEs) on OS. The study protocol allowed ≤2 dose reductions for nal-IRI and 5-FU and for up to 3 weeks. Methods: Patient who had a dose delay or reduction within the planned first 6 weeks

APA, Harvard, Vancouver, ISO, and other styles

27

Taïeb, Julien, Tim Maughan, Carsten Bokemeyer, et al. "Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data." Journal of Clinical Oncology 30, no. 15_suppl (2012): 3574. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3574.

Full text

Abstract:

3574 Background: Infusional 5-FU/FA + oxaliplatin is a widely used schedule in the first-line treatment of mCRC. In the randomized phase II OPUS study, the addition of cetuximab to one such regimen (FOLFOX4) significantly improved response and progression-free survival (PFS) in patients (pts) with KRAS wild-type (wt) mCRC. However, in the randomized phase III COIN study, a benefit for the addition of cetuximab to first-line fluoropyrimidine (administered as either infusional 5-FU or capecitabine) + oxaliplatin was not confirmed in pts with KRAS wt tumors. Methods: A pooled study-based analysis

APA, Harvard, Vancouver, ISO, and other styles

28

Wagner, A. D., W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig. "Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis." Journal of Clinical Oncology 25, no. 18_suppl (2007): 4555. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4555.

Full text

Abstract:

4555 Background: Combination chemotherapy is widely accepted for patients with advanced gastric cancer, but uncertainty remains regarding the choice of the regimen. Methods: Our objectives were to assess the effect of: 1) 5-FU/cisplatin combinations with versus without anthracyclines; 2) 5-FU/anthracycline combinations with versus without cisplatin; 3) Irinotecan versus non-irinotecan containing combination chemotherapies; 4) Docetaxel versus non-docetaxel containing combinations; on overall survival and toxicity. Search strategy: We searched: Cochrane Central Register of Controlled Trials, ME

APA, Harvard, Vancouver, ISO, and other styles

29

Schmoll, Hans-Joachim, Josep Tabernero, Jean Maroun, et al. "Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial." Journal of Clinical Oncology 33, no. 32 (2015): 3733–40. http://dx.doi.org/10.1200/jco.2015.60.9107.

Full text

Abstract:

Purpose To report the final efficacy findings and biomarker analysis from the NO16968 trial comparing bolus fluorouracil/folinic acid (FU/FA) with capecitabine plus oxaliplatin (XELOX) in resected stage III colon cancer. Patients and Methods After curative resection, patients were randomly assigned to receive XELOX, as oxaliplatin 130 mg/m2 on day 1 and capecitabine 1,000 mg/m2 twice daily on days 1 to 14 every 3 weeks, or bolus FU/FA, as the Mayo Clinic or Roswell Park regimens, for 6 months. The primary end point was disease-free survival (DFS). Secondary end points included overall survival

APA, Harvard, Vancouver, ISO, and other styles

30

Sizer, B., A. Makris, C. Barone, P. Mainwaring, and P. Eggleton. "QoL and resource use analysis of tegafur-uracil/LV or 5-FU/LV in first-line metastatic colorectal cancer (mCRC): Final results of a multicenter phase II study." Journal of Clinical Oncology 24, no. 18_suppl (2006): 3631. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3631.

Full text

Abstract:

3631 Background: Tegafur-uracil (UFT) is an effective oral fluoropyrimidine for patients with mCRC. Aims of this prospective phase II study were to evaluate quality of life (QoL), patient preference and healthcare resource use in patients receiving oral UFT/LV or i.v. 5-FU/LV as first-line therapy for mCRC. Safety and efficacy were also assessed. Methods: 243 patients in 3 countries (Austria, Italy and UK) were randomized in a 2:1 ratio to receive either UFT 300mg/m2/d + LV 90mg/d for 28d q5w, or i.v. 5-FU 425mg/m2/d + LV 20mg/m2/d for 5d q4w. Patients were assessed at baseline and every cycle

APA, Harvard, Vancouver, ISO, and other styles

31

Köhne, C. H., E. van Cutsem, J. Wils, et al. "Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986." Journal of Clinical Oncology 23, no. 22 (2005): 4856–65. http://dx.doi.org/10.1200/jco.2005.05.546.

Full text

Abstract:

Purpose To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS). Patients and Methods Four hundred thirty patients with measurable or assessable metastatic colorectal cancer were randomly assigned to receive either FA 500 mg/m2 as a 2-hour infusion and FU 2.6 g/m2 by intravenous 24-hour infusion, both administered weekly for 6 weeks, followed by a 2-week rest (Arbeitsgemeinschaft für Internistische Onkologie [AIO] arm, n = 216), or a similar schedule but with FU

APA, Harvard, Vancouver, ISO, and other styles

32

Tentoni, Nicolás, Ryan Combs, Miriam Hwang, et al. "Long-Term Outcomes of 5-Fluorouracil-Related Early-Onset Toxicities: A Retrospective Cohort Study." Cancers 16, no. 23 (2024): 4050. https://doi.org/10.3390/cancers16234050.

Full text

Abstract:

Objectives: We aimed to determine whether the occurrence of early-onset toxicities due to 5-fluorouracil (5-FU) in treatment-naive patients undergoing their first cycle of FOLFOX/FOLFIRINOX was associated with decreased overall survival, increased risk of treatment cessation, and hospitalization. Methods: This was a retrospective cohort study using patient information from community oncology practices. Patients who received their first dose of 5-FU from 1 January 2015 through 1 August 2023 were included. The occurrence of an early-onset 5-FU-related toxicity (during 5-FU infusion or up to 96 h

APA, Harvard, Vancouver, ISO, and other styles

33

Peng, Chengwei, Saad Saffo, Michael Shusterman, et al. "Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer." Journal of Clinical Oncology 41, no. 4_suppl (2023): 59. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.59.

Full text

Abstract:

59 Background: 5-Fluorouracil (5-FU) is a component of first-line treatment regimens for metastatic colorectal cancer (mCRC). Historically, 5-FU is administered as a bolus followed by an infusion. However, the bolus dose adds substantial toxicity and is often withheld in patients with limited functional status or high-risk comorbidities, but its impact on treatment outcomes remains unclear. Small studies suggest that it may be omitted. The aim of this study was to determine whether omission of the 5-FU bolus is associated with a difference in overall survival (OS). Methods: An electronic healt

APA, Harvard, Vancouver, ISO, and other styles

34

Fuchs, Charles S., Donna Niedzwiecki, Harvey J. Mamon, et al. "Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)." Journal of Clinical Oncology 35, no. 32 (2017): 3671–77. http://dx.doi.org/10.1200/jco.2017.74.2130.

Full text

Abstract:

Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy re

APA, Harvard, Vancouver, ISO, and other styles

35

Li, Jia-yi, Xuan-zhang Huang, Peng Gao, et al. "Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment." BioMed Research International 2021 (March 27, 2021): 1–21. http://dx.doi.org/10.1155/2021/8852699.

Full text

Abstract:

Background. Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the addition of oxaliplatin to adjuvant chemotherapy provides survival benefits. Methods. We performed a meta-analysis of data from the PubMed and Embase databases. We included patients with LARC who received neoadjuvant (chemo) radiotherapy and curative surgery. Overall survival (OS), disease-free survival (

APA, Harvard, Vancouver, ISO, and other styles

36

Schmidt, Jan, Ulrich Abel, Jürgen Debus, et al. "Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma." Journal of Clinical Oncology 30, no. 33 (2012): 4077–83. http://dx.doi.org/10.1200/jco.2011.38.2960.

Full text

Abstract:

Purpose Adjuvant chemotherapy prolongs survival in patients with pancreatic cancer, but its benefit is limited. Long-term survival times of up to 44 months after adjuvant chemoradioimmunotherapy in phase II trials motivated the present study. Patients and Methods Between 2004 and 2007, 132 R0/R1 resected patients received either fluorouracil (FU), cisplatin, and interferon alfa-2b (IFN α-2b) plus radiotherapy followed by two cycles of FU (arm A, n = 64) or six cycles of FU monotherapy (arm B, n = 68). One hundred ten patients (arm A, n = 53; arm B, n = 57) received at least one dose of the stu

APA, Harvard, Vancouver, ISO, and other styles

37

Modest, Dominik Paul, Meinolf Karthaus, Stefan Fruehauf, et al. "FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses." Journal of Clinical Oncology 42, no. 16_suppl (2024): 3506. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3506.

Full text

Abstract:

3506 Background: The randomized open-label phase II PanaMa trial compared FU/FA with or without pmab maintenance after mFOLFOX6+pmab induction for RAS wild-type mCRC. Updated efficacy results of the Full Analysis Set are presented. Methods: Median progression-free survival (PFS), overall survival (OS), PFS of re-induction (PFS re-ind.), time to failure of strategy (TFS), and objective response rates (ORR) were compared by log-rank test / Cox regression and Fisher’s exact test. Results: PFS was significantly (8.8 vs. 5.8 months, HR=0.73 (95%CI 0.56 – 0.94), P=0.015) and OS numerically longer (2

APA, Harvard, Vancouver, ISO, and other styles

38

Wang, Aiqing. "Cliché-ridden Online Danmei Fiction? A Case Study of Tianguan ci fu." Acta Asiatica Varsoviensia 35 (2022): 281–314. http://dx.doi.org/10.60018/acasva.iray5065.

Full text

Abstract:

Popular literature online is often misconstrued as being cliché-ridden and formulaic, and has thus not attained as much critical attention as ‘serious’ literature. I propound that popular literature published in China’s cyberspace deserves more attention and hermeneutic scrutiny, and I place an emphasis on danmei (耽美) fiction that features male-male romantic and/or erotic relationships and is predominantly published on a female-oriented website called Jinjiang Literature City. In this research, I investigate an online danmei novel entitled Tianguan ci fu (天官赐福) that concerns a homosexual roman

APA, Harvard, Vancouver, ISO, and other styles

39

Yothers, Greg, Patricia A. Ganz, Samia H. Lopa, Clifford Y. Ko, D. Lawrence Wickerham, and Norman Wolmark. "Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04." Journal of Clinical Oncology 30, no. 4_suppl (2012): 391. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.391.

Full text

Abstract:

391 Background: Preliminary results of NSABP R-04 indicated that 5-FU and cape have similar pathologic complete response (pCR) outcomes and that the addition of oxaliplatin did not improve pCR. We present PROs comparing 5-FU and cape treatments on quality of life (QoL), convenience of care (CoC), and symptoms. Methods: Clinical stage II or III rectal cancer patients were randomized to receive 5-FU (225mg/m2 5 days/wk) or cape (825 mg/m2 5 days/wk) along with RT (4,500cGy in 25 fractions over 5 wk + boost of 540-1080cGy in 3-6 daily fractions). About half of these patients were also randomized

APA, Harvard, Vancouver, ISO, and other styles

40

Liu, Guo-Chen, Jun-Ping Yan, Qing He, Xin An, Zhi-Zhong Pan, and Pei-Rong Ding. "Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis." Gastroenterology Research and Practice 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/1798285.

Full text

Abstract:

A meta-analysis was carried out to compare the efficacy and safety of capecitabine plus radiation with 5-fluorouracil (5-FU) plus radiotherapy (RT) as neoadjuvant treatment in locally advanced rectal cancer (LARC). We searched the Cochrane database, Ovid, Medline, Embase, ISI databases, and Chinese Biomedical Literature Database between January 1998 and October 2014. Trials of capecitabine compared with 5-FU plus RT as neoadjuvant treatment for LARC were considered for inclusion. RevMan software was used to analyze these data. Nine trials were included in this meta-analysis, which covered a to

APA, Harvard, Vancouver, ISO, and other styles

41

Sargent, Daniel J., Silvia Marsoni, Genevieve Monges, et al. "Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer." Journal of Clinical Oncology 28, no. 20 (2010): 3219–26. http://dx.doi.org/10.1200/jco.2009.27.1825.

Full text

Abstract:

Purpose Prior reports have indicated that patients with colon cancer who demonstrate high-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have improved survival and receive no benefit from fluorouracil (FU) -based adjuvant therapy compared with patients who have microsatellite-stable or proficient mismatch repair (pMMR) tumors. We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer. Methods MSI assay or immunohistochemistry for MMR proteins were performed on 457 patients who were previously randomly ass

APA, Harvard, Vancouver, ISO, and other styles

42

Zafar, Amna, Zsofia D. Drobni, Matthew Lei, et al. "The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm." PLOS ONE 17, no. 4 (2022): e0265767. http://dx.doi.org/10.1371/journal.pone.0265767.

Full text

Abstract:

Background Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the safety and efficacy of re-challenge with 5-FU after pre-treatment with calcium channel blockers (CCBs) and long-acting nitrates among patients 5-FU associated coronary vasospasm. Methods We conducted a retrospective study of patients with 5-FU coronary vasospasm at a single academic center. By protocol, those referred to cardio-oncology received pre-treatmen

APA, Harvard, Vancouver, ISO, and other styles

43

Freeman, Karoline, Martin Connock, Ewen Cummins, et al. "Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion." Health Technology Assessment 19, no. 91 (2015): 1–322. http://dx.doi.org/10.3310/hta19910.

Full text

Abstract:

Background5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide variations occur. Pharmacokinetic (PK) dosing is suggested to bring plasma levels into the therapeutic range to promote fewer side effects and better patient outcomes. We investigated the clinical effectiveness and cost-effectiveness of the My5-FU assay for PK dose adjustment to 5-FU therapy.ObjectivesTo systematically review the evidence on the accuracy of the My5-FU assay compared with gold standard methods [high-perform

APA, Harvard, Vancouver, ISO, and other styles

44

Sholihah, Imroatus, Meirizky Zulharini S., Amalia Miranda, Refki Riswansyah та Riris Istighfari Jenie. "Jure Leaf Extract (Nerium indium Mill.) Increased 5-Fluorouracil Sensitivity through Inhibition of NF-κB Activation and Transporter Protein in WiDr Colon Cancer Cell". Indonesian Journal of Cancer Chemoprevention 7, № 3 (2017): 87. http://dx.doi.org/10.14499/indonesianjcanchemoprev7iss3pp87-92.

Full text

Abstract:

5-Fluorouracil (5-FU) is the first line chemotherapeutic agents for colon cancer therapy. Long term used of 5-FU caused cancer cell resistency. Thus, co-chemoteraputics agent should be developed to increase cells sensitivty towards 5-FU. Jure leaf (Nerium indicum Mill) extract (JLE) contains oleandrin which has cytotoxic effect on colon cancer cell. The ain of this study was to investigated the mechanism of JLE to sensitized colon cancer cell toward 5-FU through NF-κB inhibition and MRP protein repression. JLE was extracted by soxhletation method. Based on molecular docking to MRP protein, doc

APA, Harvard, Vancouver, ISO, and other styles

45

Ikawati, Muthi, and Endah Puji Septisetyani. "Pentagamavunone-0 (PGV-0), a Curcumin Analog, Enhances Cytotoxicity of 5-Fluorouracil and Modulates Cell Cycle in WiDr Colon Cancer Cells." Indonesian Journal of Cancer Chemoprevention 9, no. 1 (2018): 23. http://dx.doi.org/10.14499/indonesianjcanchemoprev9iss1pp23-31.

Full text

Abstract:

The use of 5-fluorouracil (5-FU) in colon cancer as the primary chemotherapy has not been meet satisfactory effectiveness. Therefore, the development of new chemicals as a chemopreventive agent and a combination agent (co-chemotherapeutic agent) for colon cancer is important. Pentagamavunone-0 (2,5-bis-(4'-hydroxy-3'-methoxybenzylidine) cyclopentanone) (PGV-0), one of curcumin analogs, exhibits cytotoxic effect and apoptosis induction in various cancer cell lines, including colon cancer cell, better than curcumin. This study aimed to investigate the cytotoxic potency of PGV-0 in combination wi

APA, Harvard, Vancouver, ISO, and other styles

46

Al-Thani, Hassan, Ayman El-Menyar, Valsa Koshy, et al. "Implications of Foot Ulceration in Hemodialysis Patients: A 5-Year Observational Study." Journal of Diabetes Research 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/945075.

Full text

Abstract:

Foot ulceration (FU) remains a serious concern for patients worldwide. We analyzed the incidence, risk factors, and outcome of FU in hemodialysis (HD) patients. A retrospective cohort study was conducted for 252 HD patients who were followed up for 5 years. Patients were categorized according to whether they developed FU or not. The FU group (17%) was older and had significantly higher incidence of nephropathy, retinopathy, peripheral (PAD), coronary artery disease (CAD), and diabetes mellitus (DM) as compared to no-FU group. FU group had higher frequency of major amputation (P=0.001) and HD v

APA, Harvard, Vancouver, ISO, and other styles

47

Mohamed, Yehia I., Aliya Qayyum, Manal Hassan, et al. "Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy." Journal of Clinical Oncology 38, no. 15_suppl (2020): e16626-e16626. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16626.

Full text

Abstract:

e16626 Background: Fibrolamellar hepatocellular carcinoma (FLHCC) is a variant of HCC that comprises ∼1%–9% of all HCCs, with about 200 annual cases reported globally, most often affects younger patients (10–35 years of age) with no underlying liver disease. There is no current standard of care therapy for unresectable FLHCC. We report an analysis of the treatment outcomes, and prognostic indicators of 26 cases. Methods: We retrospectively collected clinicopathologic and treatment outcome data from 26 FLHCC patients who received interferon alfa-2b (IFN) based therapy. Median overall survival (

APA, Harvard, Vancouver, ISO, and other styles

48

Wu, Zong-Bo, Bei Wang, Xi Peng та ін. "IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27". International Journal of Ophthalmology 18, № 4 (2025): 565–74. https://doi.org/10.18240/ijo.2025.04.01.

Full text

Abstract:

AIM: To investigate the pathological features of ocular surface squamous neoplasia (OSSN) and evaluate the synergistic therapeutic effects of interferon-α2b (IFNα2b) and 5-fluorouracil (5-FU) on cellular proliferation, migration, apoptosis, and cell cycle of human oral squamous carcinoma cell line Cal27. METHODS: Tissue specimens from OSSN were processed with hematoxylin-eosin (HE) and immunofluorescence (IF) staining to characterize pathological changes. We analyzed the expression levels of four pivotal proteins involved in 5-FU metabolism: interferon alpha receptor (IFNAR), thymidylate synth

APA, Harvard, Vancouver, ISO, and other styles

49

Haller, Daniel G., Josep Tabernero, Jean Maroun, et al. "Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer." Journal of Clinical Oncology 29, no. 11 (2011): 1465–71. http://dx.doi.org/10.1200/jco.2010.33.6297.

Full text

Abstract:

PurposeThis multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with stage III colon cancer.Patients and MethodsPatients who had undergone curative resection were randomly assigned to XELOX (oxaliplatin 130 mg/m2on day 1 plus capecitabine 1,000 mg/m2twice daily on days 1 to 14 every 3 weeks for 24 weeks) or a standard bolus FU/FA adjuvant regimen (Mayo Clinic for 24 weeks or Roswell Park for 32 weeks). The primary study end point was disease-free survival (DFS).ResultsThe intention-to-t

APA, Harvard, Vancouver, ISO, and other styles

50

Testa, Luca, Azeem Latib, Nedy Brambilla, et al. "Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis." European Heart Journal 41, no. 20 (2020): 1876–86. http://dx.doi.org/10.1093/eurheartj/ehz925.

Full text

Abstract:

Abstract Aims In the last decade, transcatheter aortic valve (TAV) replacement determined a paradigm shift in the treatment of patients with severe symptomatic aortic stenosis. Data on long-term TAV performance are still limited. We sought to evaluate the clinical and haemodynamic outcomes of the CoreValve self-expandable valve up to 8-year follow-up (FU). Methods and results Nine hundred and ninety inoperable or high-risk patients were treated with the CoreValve TAV in eight Italian Centres from June 2007 to December 2011. The median FU was 4.4 years (interquartile range 1.4–6.7 years). Longe

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!